… We propose rituximab as a first-line therapy for pemphigus vulgaris and steroid-dependent
bullous … No head-to-head studies are available with respect to safety and efficacy of rituximab …

… is to evaluate the current data on the use of rituximab in the treatment of autoimmune
mucocutaneous blistering … PV is an autoimmune blistering disease that affects the skin and …

… Combining conventional systemic corticosteroids with rituximab treatment has also … treatment
and emerging therapeutics for autoimmune skin blistering diseases and highlight blistering …

… in blister formation causing erosions of the epidermis which leads to a breakdown of the barrier
function of the skin … One patient was treated with CS and ISA for mucocutaneous disease. …

… is an autoimmune blistering disease. In patients who do not respond to conventional therapy,
rituximab … The current literature on the treatment of MMP with RTX is limited. OBJECTIVE: In …

… MMP from other diseases with mucocutaneous involvement. 53 Chan … Oral cavity trauma
using ill-fitting dentures can lead to the … of protein A immunoadsorption and rituximab: a protocol …

… characterized by mucocutaneous blisters and … rituximab was used to treat non-Hodgkin's
lymphoma dawned upon a new era of targeted therapy to treat autoimmune blistering diseases. …

… The model fit was assessed using appropriate residual and goodness-of-… disease, affected
sites (mucosal only or mucosal and skin), duration of disease to the initiation of the treatment …

… factor of 12.32 in patients with mucocutaneous disease (P = .001); … written by autoimmune
blistering disease experts in … time to zero at time of treatment fit the nature of this process and …

… treatment of autoimmune mucocutaneous blistering diseases, … widespread PV involving the
skin and multiple mucosae (41). … are monitored for structural fitness and autoreactivity at five …